Latest Articles

Publication Date
All News Scientific
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients - News-Medical

Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients News-Medical

Published: May 30, 2026, 2:16 a.m.
Read Full Article
Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive

Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer OncLive

Published: May 29, 2026, 11:57 p.m.
Read Full Article
New drug approach offers hope for patients with recurrent aggressive cancers - AOL.com

New drug approach offers hope for patients with recurrent aggressive cancers AOL.com

Published: May 25, 2026, 7:45 a.m.
Read Full Article
New drug approach offers hope for patients with recurrent aggressive cancers - MSN

New drug approach offers hope for patients with recurrent aggressive cancers MSN

Published: May 24, 2026, 10:05 p.m.
Read Full Article
New drug approach offers hope for patients with recurrent aggressive cancers - Fox News

New drug approach offers hope for patients with recurrent aggressive cancers Fox News

Published: May 20, 2026, 11 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer - OncLive

Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer OncLive

Published: May 14, 2026, 12:06 a.m.
Read Full Article
Case 1: Advanced and Recurrent MMRd Endometrioid Adenocarcinoma of the Uterus - The ASCO Post

Case 1: Advanced and Recurrent MMRd Endometrioid Adenocarcinoma of the Uterus The ASCO Post

Published: April 26, 2026, 9 p.m.
Read Full Article
REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer - CancerNetwork

REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer CancerNetwork

Published: April 14, 2026, 8:09 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!